Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to developnext-generation products that improve treatment outcomes for children and adults with cancer, confirms Clarity’sTargeted Copper Theranostic (TCT) products and clinical development programs using copper-67 (Cu-67 or 67Cu) areunaffected by a recent shortage of actinium-225 (Ac-225) that has led to the delay in clinical trial recruitment1-2. Clarityalso confirms that all of its Cu-67 suppliers are based in the United States, and the Company does not source any Cu-67 from Russia.
Good on CB
Suring up supply raw materials
gees i hope Novartis and Lantheus are okay ?
News: TLX Telix Pharmaceuticals Aims Up To $4.17 Bln Valuation In US IPO, page-63
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.90 |
Change
-0.010(0.04%) |
Mkt cap ! $7.664B | |||
| Open | High | Low | Value | Volume |
| $23.00 | $23.19 | $22.40 | $16.31M | 715.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3391 | $22.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.93 | 2866 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |